For early-stage non-small-cell lung cancer (NSCLC), stereotactic body radiotherapy (SBRT) is considered the treatment of choice, if patients are inoperable because of additional medical conditions.
This is based on several prospective phase II trials, which reported consistently high rates of local tumor control. However, these studies only included small number of patients, the methodology of SBRT varied between the studies and SBRT was mainly practiced in specialized centers.
Therefore, ...
For early-stage non-small-cell lung cancer (NSCLC), stereotactic body radiotherapy (SBRT) is considered the treatment of choice, if patients are inoperable because of additional medical conditions.
This is based on several prospective phase II trials, which reported consistently high rates of local tumor control. However, these studies only included small number of patients, the methodology of SBRT varied between the studies and SBRT was mainly practiced in specialized centers.
Therefore, ...